MONTREAL, May 30, 2006 (PRIMEZONE) -- Dr. Jean-Marie Dupuy , President and CEO of Viropro Inc. (OTCBB:VPRO), is pleased to announce the appointment of Andre Bedard to the position of Financial Planning Advisor responsible for business development and international partnership agreements, and the appointment of Gino Di Iorio, C.A. as Management Director of Financial and Administrative Operations.
"I am very pleased that Mr. Bedard and Mr. Di Iorio have joined our team. Both bring with them to Viropro strong, broad experience in the biotechnological and financial sectors which includes background in development of international business projects, strategic financial planning and entrepreneurial organizational management," said Dr Jean-Marie Dupuy.
About Mr. Andre Bedard
For more than fifteen years, Mr. Bedard has been President of Marjoco Inc., a company specialized in short term profit and liquidities improvement for companies and in strategic planning for business growth. Prior to 1992, Mr. Bedard was Vice President Finance and Administration of private and public companies. He also worked for a Canadian manufacturer and distributor of pharmaceutical ethical products and he served for four years as Chief Financial Officer, Executive Vice President and Chief Operating Officer of an international biotechnology company.
About Mr. Gino Di Iorio
Before joining Viropro, Mr. Di Iorio served as Director of Finance for Draftworldwide Quebec Inc. from 2004 to 2005, a subsidiary of IPG, a world leading advertising agency, where he instituted Sarbanes-Oxley controls. Mr. Di Iorio was the Director of Finance of Sitel Corporation Canada, a leading global provider of outsourced customer support services from 1999 to 2003. At Sitel, Mr. Di Iorio oversaw the acquisition of significant government grants. Mr. Di Iorio held various other positions at Sitel allowing him to streamline operations and significantly improve reporting. Prior to Sitel, Mr. Di Iorio managed a private consultancy after obtaining auditing experience at Ernst and Young. Mr. Di Iorio graduated with B Comm. and C.A. degrees from McGill University in 1989 and 1992 respectively.
"Through these appointments, Viropro Inc. is even better positioned to meet the challenges both of its strategy of accelerated growth in the international marketplace and its revenue objectives, all while maintaining its focus on optimizing the value of Viropro assets and those of its shareholders in the long and short-term period," added Dr. Jean-Marie Dupuy.
About Viropro Inc.
Viropro Inc. operates mainly through its subsidiary Viropro International Inc. with its head office in Montreal, Canada. Viropro is a company specializing in marketing its know-how and expertise in technology transfer for industrial production of therapeutic proteins. Besides today's announcement, Viropro has concluded other strategic alliances with renowned scientific and business partners, both at the national and international levels. Viropro relies on a business model built to generate short and medium term recurrent revenues while increasing the value of stock for both the company and its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.